Panagene Inc
Panagene Inc. develops products in the field of molecular diagnostics in South Korea. Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company a… Read more
Panagene Inc - Asset Resilience Ratio
Panagene Inc (046210) has an Asset Resilience Ratio of 0.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Panagene Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Panagene Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩146.73 Million | 0.14% |
| Total Liquid Assets | ₩146.73 Million | 0.14% |
Asset Resilience Insights
- Limited Liquidity: Panagene Inc maintains only 0.14% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Panagene Inc Industry Peers by Asset Resilience Ratio
Compare Panagene Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Macrogen Inc
KQ:038290 |
Biotechnology & Medical Research | 3.56% |
|
Cell Biotech Co. Ltd
KQ:049960 |
Biotechnology & Medical Research | 54.84% |
|
Bioneer Corporation
KQ:064550 |
Biotechnology & Medical Research | 14.92% |
|
MEDIPOST Co. Ltd
KQ:078160 |
Biotechnology & Medical Research | 0.72% |
|
Biotoxtech Co. Ltd
KQ:086040 |
Biotechnology & Medical Research | 7.17% |
|
Peptron Inc
KQ:087010 |
Biotechnology & Medical Research | 57.41% |
|
Hadasit Bio
TA:HDST |
Biotechnology & Medical Research | 57.00% |
|
Pluristem
TA:PSTI |
Biotechnology & Medical Research | 48.26% |
Annual Asset Resilience Ratio for Panagene Inc (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Panagene Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 55.59% | ₩60.93 Billion | ₩109.61 Billion | -28.94pp |
| 2023-12-31 | 84.53% | ₩76.85 Billion | ₩90.91 Billion | +27.00pp |
| 2022-12-31 | 57.53% | ₩19.95 Billion | ₩34.67 Billion | +2.34pp |
| 2021-12-31 | 55.19% | ₩17.61 Billion | ₩31.91 Billion | +11.26pp |
| 2020-12-31 | 43.93% | ₩11.96 Billion | ₩27.23 Billion | +15.76pp |
| 2019-12-31 | 28.17% | ₩6.14 Billion | ₩21.79 Billion | -7.36pp |
| 2018-12-31 | 35.53% | ₩8.55 Billion | ₩24.08 Billion | +2.84pp |
| 2017-12-31 | 32.69% | ₩9.12 Billion | ₩27.90 Billion | -0.24pp |
| 2016-12-31 | 32.93% | ₩10.87 Billion | ₩33.02 Billion | +24.70pp |
| 2012-12-31 | 8.23% | ₩2.10 Billion | ₩25.51 Billion | +2.58pp |
| 2011-12-31 | 5.66% | ₩2.40 Billion | ₩42.42 Billion | +3.02pp |
| 2010-12-31 | 2.64% | ₩1.01 Billion | ₩38.31 Billion | -0.34pp |
| 2009-12-31 | 2.98% | ₩979.25 Million | ₩32.90 Billion | -3.35pp |
| 2008-12-31 | 6.33% | ₩3.18 Billion | ₩50.28 Billion | +1.99pp |
| 2007-12-31 | 4.34% | ₩2.20 Billion | ₩50.68 Billion | +3.13pp |
| 2006-12-31 | 1.21% | ₩708.56 Million | ₩58.67 Billion | +0.86pp |
| 2005-12-31 | 0.34% | ₩218.47 Million | ₩63.42 Billion | -- |